

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042474

International filing date: 15 December 2004 (15.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/529,470
Filing date: 15 December 2003 (15.12.2003)

Date of receipt at the International Bureau: 24 January 2004 (24.01.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1272338

THE UNITED STATES OF AMERICA

TO ALL WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 11, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/529,470

FILING DATE: *December 15, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/42474



Certified By



Jon W Dudas

Under Secretary
of Commerce for Intellectual Property
and Acting Director of the
United States Patent and Trademark Office

13049 U.S.PTO
121503

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

16018 U.S.PTO
60/529470

121503


Express Mail Label No. _____

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Todd Duncan	Campbell	Petaluma, California			
Additional inventors are being named on the One separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max) Alginate Cap with Therapeutic and Cellular Components for Treating Vulnerable Plaque					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number:					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name	James F. Hensel				
Address	2911 SW Orchard Hill Place				
Address					
City	Lake Oswego	State	OR	Zip	97035-1194
Country	USA	Telephone	503-244-3232	Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages	Cover and 35 Pages	<input type="checkbox"/>	CD(s), Number _____		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	Thirteen	<input type="checkbox"/>	Other (specify) _____		
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	FILING FEE Amount (\$)				
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.	\$80				
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: _____					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Date December 15, 2003

Respectfully submitted,

SIGNATURE 

TYPED or PRINTED NAME James F. Hensel

TELEPHONE 503-244-3232

REGISTRATION NO. _____

(if appropriate) _____

Docket Number: _____

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT
 This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
James Finley	Hensel	Lake Oswego, Oregon

[Page 2 of 2]

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

13049
121503


U.S.P.T.O.

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL		Complete if Known	
for FY 2004		Application Number	
<i>Effective 10/01/2003. Patent fees are subject to annual revision.</i>		Filing Date	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		First Named Inventor	Todd Duncan Campbell
TOTAL AMOUNT OF PAYMENT (\$ 80)		Examiner Name	
		Art Unit	
		Attorney Docket No.	

METHOD OF PAYMENT (check all that apply)		FEES CALCULATION (continued)																																																																									
<input checked="" type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input type="checkbox"/> Deposit Account: Deposit Account Number Deposit Account Name		3. ADDITIONAL FEES <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> </tr> </thead> <tbody> <tr> <td>Fee Code (\$)</td> <td>Fee Code (\$)</td> </tr> <tr> <td>Fee Code (\$)</td> <td>Fee Code (\$)</td> </tr> <tr> <td>Fee Code (\$)</td> <td>Fee Description</td> </tr> <tr> <td>Fee Code (\$)</td> <td>Fee Paid</td> </tr> <tr> <td>1051 130</td> <td>2051 65 Surcharge - late filing fee or oath</td> </tr> <tr> <td>1052 50</td> <td>2052 25 Surcharge - late provisional filing fee or cover sheet</td> </tr> <tr> <td>1053 130</td> <td>1053 130 Non-English specification</td> </tr> <tr> <td>1812 2,520</td> <td>1812 2,520 For filing a request for ex parte reexamination</td> </tr> <tr> <td>1804 920*</td> <td>1804 920* Requesting publication of SIR prior to Examiner action</td> </tr> <tr> <td>1805 1,840*</td> <td>1805 1,840* Requesting publication of SIR after Examiner action</td> </tr> <tr> <td>1251 110</td> <td>2251 55 Extension for reply within first month</td> </tr> <tr> <td>1252 420</td> <td>2252 210 Extension for reply within second month</td> </tr> <tr> <td>1253 950</td> <td>2253 475 Extension for reply within third month</td> </tr> <tr> <td>1254 1,480</td> <td>2254 740 Extension for reply within fourth month</td> </tr> <tr> <td>1255 2,010</td> <td>2255 1,005 Extension for reply within fifth month</td> </tr> <tr> <td>1401 330</td> <td>2401 165 Notice of Appeal</td> </tr> <tr> <td>1402 330</td> <td>2402 165 Filing a brief in support of an appeal</td> </tr> <tr> <td>1403 290</td> <td>2403 145 Request for oral hearing</td> </tr> <tr> <td>1451 1,510</td> <td>1451 1,510 Petition to institute a public use proceeding</td> </tr> <tr> <td>1452 110</td> <td>2452 55 Petition to revive - unavoidable</td> </tr> <tr> <td>1453 1,330</td> <td>2453 665 Petition to revive - unintentional</td> </tr> <tr> <td>1501 1,330</td> <td>2501 665 Utility issue fee (or reissue)</td> </tr> <tr> <td>1502 480</td> <td>2502 240 Design issue fee</td> </tr> <tr> <td>1503 640</td> <td>2503 320 Plant issue fee</td> </tr> <tr> <td>1460 130</td> <td>1460 130 Petitions to the Commissioner</td> </tr> <tr> <td>1807 50</td> <td>1807 50 Processing fee under 37 CFR 1.17(q)</td> </tr> <tr> <td>1806 180</td> <td>1806 180 Submission of Information Disclosure Stmt</td> </tr> <tr> <td>8021 40</td> <td>8021 40 Recording each patent assignment per property (times number of properties)</td> </tr> <tr> <td>1809 770</td> <td>2809 385 Filing a submission after final rejection (37 CFR 1.129(a))</td> </tr> <tr> <td>1810 770</td> <td>2810 385 For each additional invention to be examined (37 CFR 1.129(b))</td> </tr> <tr> <td>1801 770</td> <td>2801 385 Request for Continued Examination (RCE)</td> </tr> <tr> <td>1802 900</td> <td>1802 900 Request for expedited examination of a design application</td> </tr> <tr> <td colspan="2">Other fee (specify) _____</td> </tr> <tr> <td colspan="2">*Reduced by Basic Filing Fee Paid</td> <td colspan="2">SUBTOTAL (3) (\$ 0)</td> </tr> </tbody> </table>		Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Code (\$)	Fee Paid	1051 130	2051 65 Surcharge - late filing fee or oath	1052 50	2052 25 Surcharge - late provisional filing fee or cover sheet	1053 130	1053 130 Non-English specification	1812 2,520	1812 2,520 For filing a request for ex parte reexamination	1804 920*	1804 920* Requesting publication of SIR prior to Examiner action	1805 1,840*	1805 1,840* Requesting publication of SIR after Examiner action	1251 110	2251 55 Extension for reply within first month	1252 420	2252 210 Extension for reply within second month	1253 950	2253 475 Extension for reply within third month	1254 1,480	2254 740 Extension for reply within fourth month	1255 2,010	2255 1,005 Extension for reply within fifth month	1401 330	2401 165 Notice of Appeal	1402 330	2402 165 Filing a brief in support of an appeal	1403 290	2403 145 Request for oral hearing	1451 1,510	1451 1,510 Petition to institute a public use proceeding	1452 110	2452 55 Petition to revive - unavoidable	1453 1,330	2453 665 Petition to revive - unintentional	1501 1,330	2501 665 Utility issue fee (or reissue)	1502 480	2502 240 Design issue fee	1503 640	2503 320 Plant issue fee	1460 130	1460 130 Petitions to the Commissioner	1807 50	1807 50 Processing fee under 37 CFR 1.17(q)	1806 180	1806 180 Submission of Information Disclosure Stmt	8021 40	8021 40 Recording each patent assignment per property (times number of properties)	1809 770	2809 385 Filing a submission after final rejection (37 CFR 1.129(a))	1810 770	2810 385 For each additional invention to be examined (37 CFR 1.129(b))	1801 770	2801 385 Request for Continued Examination (RCE)	1802 900	1802 900 Request for expedited examination of a design application	Other fee (specify) _____		*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$ 0)	
Large Entity	Small Entity																																																																										
Fee Code (\$)	Fee Code (\$)																																																																										
Fee Code (\$)	Fee Code (\$)																																																																										
Fee Code (\$)	Fee Description																																																																										
Fee Code (\$)	Fee Paid																																																																										
1051 130	2051 65 Surcharge - late filing fee or oath																																																																										
1052 50	2052 25 Surcharge - late provisional filing fee or cover sheet																																																																										
1053 130	1053 130 Non-English specification																																																																										
1812 2,520	1812 2,520 For filing a request for ex parte reexamination																																																																										
1804 920*	1804 920* Requesting publication of SIR prior to Examiner action																																																																										
1805 1,840*	1805 1,840* Requesting publication of SIR after Examiner action																																																																										
1251 110	2251 55 Extension for reply within first month																																																																										
1252 420	2252 210 Extension for reply within second month																																																																										
1253 950	2253 475 Extension for reply within third month																																																																										
1254 1,480	2254 740 Extension for reply within fourth month																																																																										
1255 2,010	2255 1,005 Extension for reply within fifth month																																																																										
1401 330	2401 165 Notice of Appeal																																																																										
1402 330	2402 165 Filing a brief in support of an appeal																																																																										
1403 290	2403 145 Request for oral hearing																																																																										
1451 1,510	1451 1,510 Petition to institute a public use proceeding																																																																										
1452 110	2452 55 Petition to revive - unavoidable																																																																										
1453 1,330	2453 665 Petition to revive - unintentional																																																																										
1501 1,330	2501 665 Utility issue fee (or reissue)																																																																										
1502 480	2502 240 Design issue fee																																																																										
1503 640	2503 320 Plant issue fee																																																																										
1460 130	1460 130 Petitions to the Commissioner																																																																										
1807 50	1807 50 Processing fee under 37 CFR 1.17(q)																																																																										
1806 180	1806 180 Submission of Information Disclosure Stmt																																																																										
8021 40	8021 40 Recording each patent assignment per property (times number of properties)																																																																										
1809 770	2809 385 Filing a submission after final rejection (37 CFR 1.129(a))																																																																										
1810 770	2810 385 For each additional invention to be examined (37 CFR 1.129(b))																																																																										
1801 770	2801 385 Request for Continued Examination (RCE)																																																																										
1802 900	1802 900 Request for expedited examination of a design application																																																																										
Other fee (specify) _____																																																																											
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$ 0)																																																																									
Total Claims <input type="checkbox"/> -20** = <input type="checkbox"/> X <input type="checkbox"/> = <input type="checkbox"/> Independent Claims <input type="checkbox"/> - 3** = <input type="checkbox"/> X <input type="checkbox"/> = <input type="checkbox"/> Multiple Dependent <input type="checkbox"/> = <input type="checkbox"/>		2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> </tr> <tr> <th>Fee Code (\$)</th> <th>Fee Code (\$)</th> </tr> </thead> <tbody> <tr> <td>1202 18</td> <td>2202 9 Claims in excess of 20</td> </tr> <tr> <td>1201 86</td> <td>2201 43 Independent claims in excess of 3</td> </tr> <tr> <td>1203 290</td> <td>2203 145 Multiple dependent claim, if not paid</td> </tr> <tr> <td>1204 86</td> <td>2204 43 ** Reissue independent claims over original patent</td> </tr> <tr> <td>1205 18</td> <td>2205 9 ** Reissue claims in excess of 20 and over original patent</td> </tr> <tr> <td colspan="2">SUBTOTAL (2) (\$ 0)</td> </tr> </tbody> </table>		Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	1202 18	2202 9 Claims in excess of 20	1201 86	2201 43 Independent claims in excess of 3	1203 290	2203 145 Multiple dependent claim, if not paid	1204 86	2204 43 ** Reissue independent claims over original patent	1205 18	2205 9 ** Reissue claims in excess of 20 and over original patent	SUBTOTAL (2) (\$ 0)																																																									
Large Entity	Small Entity																																																																										
Fee Code (\$)	Fee Code (\$)																																																																										
1202 18	2202 9 Claims in excess of 20																																																																										
1201 86	2201 43 Independent claims in excess of 3																																																																										
1203 290	2203 145 Multiple dependent claim, if not paid																																																																										
1204 86	2204 43 ** Reissue independent claims over original patent																																																																										
1205 18	2205 9 ** Reissue claims in excess of 20 and over original patent																																																																										
SUBTOTAL (2) (\$ 0)																																																																											

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY			
Name (Print/Type)	James F. Hensel	Registration No. (Attorney/Agent)	Telephone 503-244-3232
Signature		Date	12/15/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**Endolumen Therapeutics, Inc.
2911 SW Orchard Hill Place
Lake Oswego, OR 97035**

December 15, 2003

Commissioner for Patents
Mail Stop Provisional Patent Application
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

Via Express Mail

RE: Provisional Patent Application

Dear Commissioner:

Please find enclosed the following:

Provisional Patent Application Titled "ALGINATE CAP WITH THERAPEUTIC AND CELLULAR COMPONENTS FOR TREATING VULNERABLE PLAQUE" including:

- a. Provisional Application Coversheet (two pages);
- b. Fee Transmittal;
- c. Specification consisting of a cover page and 35 additional pages;
- d. Drawings consisting of 13 pages; and
- e. Check payable to the Commissioner of Patents in the Amount of \$80 (claiming small business entity status).

Warm regards,

James F. Hensel

U.S. PROVISIONAL PATENT APPLICATION

**ALGINATE CAP WITH THERAPEUTIC AND CELLULAR
COMPONENTS FOR TREATING VULNERABLE PLAQUE**

INVENTORS

Name: Todd Duncan Campbell

Name: James Finley Hensel

CORRESPONDENCE:

James F. Hensel

2911 SW Orchard Hill Place

Lake Oswego, OR 97035-1194

ALGINATE CAP WITH THERAPEUTIC AND CELLULAR COMPONENTS FOR TREATING VULNERABLE PLAQUE

5

FIELD OF THE INVENTION

The present invention relates generally to treatment of vulnerable plaque, and
10 more specifically to in-situ formed alginate caps with therapeutic and cellular
components to cover vulnerable plaque in a vessel.

BACKGROUND OF THE INVENTION

Although the buildup of cholesterol and other fatty substances on blood vessel
15 walls has received much attention in preventative measures and treatments for vascular
diseases, the development and rupture of non-occlusive, soft atherosclerotic or vulnerable
plaques in coronary arteries may be a larger contributor to myocardial infarction, known
commonly as a heart attack.

Research suggests that vulnerable plaques have a dense infiltrate of macrophages
20 within a thin fibrous cap that overlies a pool of lipid, a fat-like compound. Vulnerable
plaque is formed from droplets of lipid that are absorbed by an artery, which can cause
the release of proteins called cytokines that exacerbate inflammation. The cytokines act
as an adhesive, attracting monocytes, so-called immune-system cells, to the artery wall
where they push into the tissue of the wall. The monocytes change into macrophages,
25 cells of the reticuloendothelial system, which begin to soak up fat droplets and form a
plaque with a thin covering.

The rupture of the thin covering of the vulnerable plaques, due to inflammatory
processes and mechanical stress like increased blood pressure, results in the thin covering
over the plaque cracking and exposing blood to the lipid core and other plaque
30 components. Vulnerable plaque erodes or ruptures, creating a raw tissue surface that
forms scabs, and pieces of plaque that break off may accumulate in the coronary artery to
create a thrombus of sufficient size to slow down or stop blood flow.

Vulnerable plaque is ingrained under the arterial wall and is difficult to detect with conventional means such as angiography or fluoroscopy. Thermography, which is capable of detecting a temperature difference between atherosclerotic plaque and healthy vessel walls, is one of the imaging methods being pursued for locating vulnerable plaque.

5 A significant amount of medical research continues to focus on the prevention and treatment of the softer vulnerable plaque, as well as the treatment of harder atherosclerotic plaque within vessels. One promising area of medical study is local drug delivery to diseased or traumatized treatment areas. For example, in an effort to prevent restenosis provoked by medical procedures, systems and methods have been developed to
10 locally deliver pharmacological agents such as rapamycin, an immunosuppressant known for its anti-proliferation properties, or paclitaxel, a chemotherapy agent and microtubular stabilizer that causes cells to stop dividing due to a mitotic block between metaphase and anaphase of cell division. Some of these inhibitory pharmacological agents have the potential to interfere or delay healing, weakening the structure or elasticity of the newly
15 healed vessel wall and damaging surrounding endothelium and/or other medial smooth muscle cells. Dead and dying cells release mitogenic agents that may stimulate additional smooth muscle cell proliferation and exacerbate stenosis.

The focused delivery of therapeutically effective drug levels is critical for optimizing the association of the inhibitory drug with its intracellular target, while
20 minimizing intercellular redistribution of the drug to neighboring cells. Thus, various systems for delivering pharmaceutical agents to a targeted area of a vessel wall have been proposed.

One drug-delivery system receiving much attention in recent years involves drug-eluting coatings for stents, which allow drugs to release during extended periods of time
25 such as several weeks or months. For example, a medical device coating may express one or more therapeutic agents to inhibit smooth muscle cell proliferation, as described in “Implants Possessing a Surface of Endothelial Cells Genetically-Modified to Inhibit Intimal Thickening,” Williams et al., U.S. Patent No. 5,957,972 granted September 28, 1999. The coating includes a monolayer of endothelial cells that are genetically modified
30 to express the therapeutic agents and most specifically, the protein interferon-gamma.

An anti-thrombogenic, lubricious coating for metallic medical devices has been developed to release sustained, therapeutic amounts of nitric oxide, as disclosed in "Nitric Oxide-Releasing Metallic Medical Devices," Fitzhugh et al., U.S. Patent No. 6,270,779 granted August 7, 2001.

- 5 Researchers are trying to construct softer and more flexible implant stents of shaped polymeric hydrogels, as suggested in "Medical Devices Comprising Ionically and Non-Ionically Crosslinked Polymer Hydrogels Having Improved Mechanical Properties," Ronan et al., U.S. Patent No. 6,387,978 issued May 14, 2002. Some of these polymeric hydrogel stents are at least partially bioabsorbable, as disclosed in "Stent-Graft with
- 10 Bioabsorbable Structural Support," Burnside et al., U.S. Patent No. 6,626,939 issued September 30, 2003.

Biodegradable polymeric liners have been cast *in situ* for supporting an prostatic urethra, as disclosed in "Compositions, Methods and Devices for Treatment of Urethral Disorders," Slepian et al., U.S. Patent Application No. 2003/0103932 published June 5, 15 2003. The lining supports the urethra and peri-urethral tissue during healing and then biodegrades. Alternatively, the polymer coating is applied to a structural material such as a stent, to decrease adhesion and/or provide release of drugs to enhance healing. Polymers may be selected to minimize inflammation, secondary bleeding and late fibrotic scarring and stricturing.

- 20 Biodegradable polymers have also been used to cover and seal an interior surface area of a tissue lumen, described in "Biodegradable Polymeric Endoluminal Sealing Process, Apparatus and Polymeric Products for Use Therein," Slepian et al., U.S. Patent No. 6,443,941 granted September 3, 2002. The polymer may be delivered as a monomer or prepolymer solution, or as an at least partially preformed layer on a catheter balloon.

25 Despite all the advances in the percutaneous procedures and endoluminal treatments mentioned above, inflammation and damage to vessel tissue continue to be a significant problem. Therefore, the need remains for improved systems, methods and devices for treating diseased blood vessels, minimizing or eliminating damage to surrounding tissue during procedures, and preventing inflammation of diseased areas.

- 30 The desirable treatment of specific tissues provides sustained local delivery of therapeutic

compositions to help tissue to heal while avoiding excessive drug levels. More specifically, improved methods and devices for treating vulnerable plaque protect diseased areas from rupture, minimize inflammation, control the dosage and delivery of therapeutic components over extended periods of time; and treat or prevent undesirable medical conditions within a vessel.

SUMMARY OF THE INVENTION

One aspect of the invention is an alginate cap for vulnerable plaque in a vessel of a mammalian body. The alginate cap includes an alginate matrix in contact with the 10 vulnerable plaque and an endoluminal wall of the vessel, with a central lumen axially extending through the alginate matrix to allow fluid flow through the vessel while the alginate matrix covers the vulnerable plaque.

Another aspect of the invention is a method of treating vulnerable plaque in a vessel of a mammalian body. An alginate cap is formed within the vessel, and a 15 therapeutic agent is eluted from one of a therapeutic component or a cellular component dispersed within the alginate cap. The alginate cap is in contact with the vulnerable plaque and an endoluminal wall of the vessel, and has a central lumen axially extending through the alginate cap.

Another aspect of the invention is a system for treating vulnerable plaque in a 20 vessel of a mammalian body, including a cap formation catheter having a catheter body, a dog-boned formation balloon attached to the catheter body near a distal end of the catheter body, and an alginate-delivery lumen within the catheter body. An alginate cap is formed over the vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal 25 wall of the vessel when the formation balloon is inflated.

Another aspect of the invention is a method of forming an alginate cap in a vessel 30 of a mammalian body. A cap formation catheter having a catheter body is positioned in the vessel. A dog-boned formation balloon attached to the catheter body near a distal end of the catheter body is inflated. An alginate solution is injected through an alginate-delivery lumen into a cavity formed between the inflated formation balloon and an

endoluminal wall of the vessel. The alginate solution is hardened to form the alginate cap over vulnerable plaque in a portion of the vessel.

Another aspect of the invention is a system for treating vulnerable plaque in a vessel of a mammalian body. The system includes a cap formation catheter having a catheter body. A distal occlusion balloon is attached to the catheter body near a distal end of the catheter body. A proximal occlusion balloon is attached to the catheter body proximal to the distal occlusion balloon. A medial formation balloon is attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon. An alginate-delivery lumen is included within the catheter body. An alginate cap is formed over the vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the medial formation balloon and an endoluminal wall of the vessel when the distal occlusion balloon and the proximal occlusion balloon are inflated.

Another aspect of the invention is a method of forming an alginate cap in a vessel of a mammalian body. In this embodiment, a cap formation catheter having a catheter body is positioned in the vessel. A distal occlusion balloon attached to the catheter body near a distal end of the catheter body is inflated and a proximal occlusion balloon attached to the catheter body proximal to the distal balloon is inflated. A medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon is inflated. An alginate solution is injected through an alginate-delivery lumen into a cavity formed between the inflated distal occlusion balloon, the inflated proximal occlusion balloon, the inflated medial formation balloon, and an endoluminal wall of the vessel. The alginate solution is hardened to form the alginate cap to cover the vulnerable plaque in a portion of the vessel.

Another aspect of the invention is a system for forming an alginate cap in a mammalian body, including a cap formation catheter having a catheter body, an angioplasty balloon attached to the catheter body near a distal end of the catheter body, a formation balloon attached to the catheter body proximal to the angioplasty balloon, and an alginate-delivery lumen within the catheter body. An alginate linking agent is disposed on a surface of the angioplasty balloon. An alginate cap is formed over the

vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated.

Another aspect of the invention is a method of forming an alginate cap in a vessel
5 of a mammalian body. In this embodiment, a cap formation catheter having a catheter body is positioned at a first location in the vessel. An angioplasty balloon attached to the catheter body near a distal end of the catheter and having an alginate linking agent disposed on a surface of the angioplasty balloon is inflated. The alginate linking agent is deposited on an endoluminal wall of the vessel. The angioplasty balloon is deflated and
10 repositioned at a second location in the vessel distal to the first location. The angioplasty balloon is re-inflated. A formation balloon attached to the catheter body proximal to the angioplasty balloon is inflated. An alginate solution is injected through an alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel. The alginate solution is hardened by the alginate linking agent
15 deposited on the endoluminal wall of the vessel, and the vulnerable plaque in a portion of the vessel is covered.

Another aspect of the invention is a system for forming an alginate cap in a vessel of a mammalian body, including a cap formation catheter having a catheter body and an alginate-delivery lumen within the catheter body, and at least one formation balloon
20 attached proximal to a distal end of the catheter body. An alginate cap is formed in the vessel when the cap formation catheter is inserted into the vessel and an alginate solution is injected through the alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel.

Another aspect of the invention is a method of forming an alginate cap in a vessel
25 of a mammalian body. A cap formation catheter with at least one formation balloon is inserted into the vessel. An alginate solution is injected into a cavity formed between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated. The alginate solution is hardened to form the alginate cap, and the cap formation catheter is withdrawn from the vessel. The formed alginate cap is in contact

with the endoluminal wall of the vessel and includes a central lumen axially extending through the alginate cap.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The aforementioned, and other features and advantages of the invention will become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention rather than limiting, the scope of the invention being defined by the appended claims and equivalents
10 thereof. Various embodiments of the present invention are illustrated by the accompanying figures, the figures not necessarily drawn to scale, wherein:

FIG. 1 illustrates a system for treating vulnerable plaque in a vessel of a mammalian body, in accordance with one embodiment of the current invention;

15 **FIG. 2** illustrates a longitudinal cross-sectional view of an alginate cap, in accordance with one embodiment of the current invention;

FIG. 3 illustrates a cross-sectional view of the alginate cap of **FIG. 2**;

FIG. 4 is a flow diagram of a method for treating vulnerable plaque in a vessel of a mammalian body, in accordance with another embodiment of the current invention;

20 **FIG. 5** illustrates a longitudinal cross-sectional view of an alginate cap being formed within a vessel of a mammalian body, in accordance with one embodiment of the current invention;

FIG. 6 illustrates a longitudinal cross-sectional view of an alginate cap formed within a vessel of a mammalian body, in accordance with one embodiment of the current invention;

25 **FIG. 7** is a flow diagram of a method for forming an alginate cap in a vessel of a mammalian body, in accordance with one embodiment of the current invention;

FIG. 8 illustrates a longitudinal cross-sectional view of an alginate cap being formed within a vessel of a mammalian body, in accordance with another embodiment of the current invention;

FIG. 9 illustrates a longitudinal cross-sectional view of an alginate cap formed within a vessel of a mammalian body, in accordance with another embodiment of the current invention;

5 **FIG. 10** is a flow diagram of a method for forming an alginate cap in a vessel of a mammalian body, in accordance with another embodiment of the current invention;

FIG. 11a, FIG. 11b, FIG. 11c, FIG. 11d, FIG. 11e, and FIG. 11f illustrate longitudinal cross-sectional views of an alginate cap corresponding to steps in a method of forming an alginate cap, in accordance with another embodiment of the current invention;

10 **FIG. 12** illustrates a longitudinal cross-sectional view of an alginate cap formed within a vessel of a mammalian body, in accordance with another embodiment of the current invention; and

FIG. 13 is a flow diagram of a method for forming an alginate cap in a vessel of a mammalian body, in accordance with another embodiment of the current invention.

15

DETAILED DESCRIPTION OF THE INVENTION

FIG. 1 illustrates a system for treating vulnerable plaque in a vessel **50** of a mammalian body **52**, in accordance with one embodiment of the present invention. The system includes a cap formation catheter **10** having a catheter body **12**. One or more 20 inflatable balloons such as a dog-boned formation balloon **20** are attached to catheter body **12** near a distal end **14** of catheter body **12**. Alginate cap **30** is formed from an alginate solution **60** injected through an alginate-delivery lumen **18** of catheter body **12** into a portion **56** of vessel **50** to cover vulnerable plaque **58**. Alginate solution **60** is injected into a cavity **22** between formation balloon **20** and an endoluminal wall **54** of vessel **50** when formation balloon **20** is inflated.

The formed alginate cap **30** includes an alginate matrix **32** that is in contact with endoluminal wall **54** of vessel **50** and covers vulnerable plaque **58**. A central lumen **42** axially extending through alginate matrix **32** permits fluids to flow through vessel **50**.

30 Inflation lumens within catheter body **12** allow an inflation fluid **48** to be transported from a proximal end **16** of cap formation catheter **10** into and out of the

interior regions of one or more inflation balloons attached to catheter body 12. When cap formation catheter 10 is appropriately positioned within vessel 50, exemplary alginate cap 30 is formed by inflating formation balloon 20, creating a cavity 22 between an outer surface of formation balloon 20 and endoluminal wall 54 of vessel 50. A guidewire 8
5 may be used to position cap formation catheter 10 at a desired location in body 52, as is known in the art. Cap formation catheter 10 may have an over-the-wire, rapid exchange, monorail, or other type of catheter configuration, as is known in the art. An alginate solution 60 is injected through a port at proximal end 16, through alginate-delivery lumen 18, and into cavity 22, where it hardens to form alginate cap 30 against endoluminal wall
10 54 of the vessel. Alginate cap 30 provides some mechanical support for vessel 50, and may elute and locally deliver one or more therapeutic agents 40 from therapeutic and cellular components contained therein to treat vulnerable plaque 58 and nearby tissues.

Alginate cap 30 provides a mechanism for controlled, time-release characteristics of therapeutic agents 40 from any therapeutic components 34 and cellular components 36
15 within an alginate matrix 32 of alginate cap 30. Delivery of therapeutic agents 40 may occur over days, weeks, months and even years after formation. In one embodiment, the invention provides localized delivery of one or more therapeutic agents 40 from therapeutic components 34 dispersed within alginate cap 30 when alginate cap 30 is formed within a vessel 50 of the mammalian recipient. In another embodiment, the
20 invention provides long-term delivery of one or more therapeutic agents 40 via an alginate matrix 32 suitable for maintaining encapsulated cells and aggregates of viable cells from transplanted or implanted cells that produce such therapeutic agents.

Alginate cap 30 may include one or more therapeutic components 34 dispersed within alginate matrix 32, which controls the elution of a therapeutic agent 40 from
25 alginate cap 30. Therapeutic component 34 includes, for example, an anti-coagulant, an anti-platelet drug, an anti-thrombotic drug, an anti-proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammatant, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin
30 analog, paclitaxel, a paclitaxel analog, a coumadin therapy, a lipase, or a combination

thereof. Therapeutic agents **40** released from alginate cap **30** include, for example, therapeutic components **34** themselves or portions thereof.

Alternatively, alginate cap **30** may include one or more cellular components **36** dispersed within alginate matrix **32** to provide therapeutic agent **40**. Alginate matrix **32** provides an immune barrier for cellular components **36** and controls the elution of therapeutic agents **40** from alginate cap **30**. Cellular component **36** includes, for example, endothelial cells, manipulated cells of designer deoxyribonucleic acid, host-derived cells from a host source, donor-derived cells from a donor source, pharmacologically viable cells, freeze-dried cells, or a combination thereof. Therapeutic components **34** and cellular components **36** may elute one or more therapeutic agents **40** into surrounding tissue.

Alginate matrix **32** may include selected therapeutic components **34** and cellular components **36** that produce therapeutic agents **40** for elution from alginate matrix **32** of alginate cap **30**. When cellular components **36** are selected, alginate matrix **32** may serve as an immune barrier so that the immune system of the recipient does not recognize and destroy cellular component **36** contained within alginate matrix **32**, or terminate the production of therapeutic agents **40**. Meanwhile, alginate matrix **32** still allows for the metabolic transfer of nutrients, wastes, and therapeutic proteins and agents to pass through alginate matrix **32** into surrounding vessel **50**. Therapeutic agents **40** are delivered in close proximity to the treatment site and released from alginate cap **30**. Alginate cap **30** with therapeutic components **34** and cellular components **36** provides long-term expression of the therapeutic agents **40**.

Therapeutic agents **40** from cellular components **36** include, for example, a residue, a byproduct, or natural excretion from the cells. Therapeutic agents **40** include, for example, nitric oxide. Other examples of released therapeutic agents **40** include vascular endothelial growth factor, a biological anti-inflammatory agent, vitamin C, acetylsalicylic acid, a lipid-lowering compound, a high-density lipoprotein cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a blood-thinning agent, a coumadin material, an anti-cancer agent, a therapeutic component, a cellular component, or a combination thereof.

Alginate cap 30 having therapeutic components 34 or cellular components 36 may help prevent vulnerable-plaque erosion or rupture by eluting of one or more therapeutic agents 40 near the tissue needing treatment. For example, the eluted therapeutic agents may reduce inflammation in the vicinity of alginate cap 30 and within the treated area of vessel 50.

Living cells or other biomaterials and therapeutic compounds may be immobilized in alginate matrix 32 such as an alginate gel. Cells immobilized in alginate gels maintain good viability during long-term culture, due in part to the mild environment of the gel network. Alginate gel provides a physically protective barrier for immobilized cells and tissue, and inhibits immunological reactions of the host. Alginate matrix 32 provides a location that is viable and productive for cellular components 36, since alginate matrix 32 allows the diffusion of nutrients to the cell, diffusion of respiratory byproducts to the surrounding area, and diffusion of selected therapeutic components 34 in an unaltered condition from alginate matrix 32. In some cases, alginate matrix 32 serves as an immune barrier while providing for diffusive transport for therapeutic and cellular materials. The immune barrier properties of alginate matrix 32 are particularly useful for non-host derived cell sources, or manipulated cells of designer deoxyribonucleic acid (DNA).

One example of a cellular component 36 is endothelial cells that produce nitric oxide, a regulating molecule for smooth muscle cell quiescence and maintenance of vascular smooth muscle cells in the non-proliferative stage. A patient's own endothelial cells from, for example, microvascular adipose tissue, may be harvested and mixed with an alginate solution, and formed along with alginate matrix 32 into alginate cap 30. Upon implantation, the endothelial cells remain viable and locally produce nitric oxide to regulate and maintain the quiescent nature of smooth muscle cells, which can be a contributor to the production and recruitment of fibroblasts from the media and adventitia of arteries. With the continued long-term production of nitric oxide from the translocated endothelial cells, vascular patency may be maintained for a substantially longer period following cap formation.

Long-term administration of at least one therapeutic agent **40** such as nitric oxide may be provided to vessel **50** that is diseased or traumatized. For example, disruption of the endothelial lining in a diseased portion of vessel **50** may result in the reduction of nitric oxide production, leading to the loss of regulation of the smooth muscle cells.

- 5 Endothelial-derived nitric oxide is a naturally occurring regulation compound. The endothelial cell lining of vessels **50** produces the nitric oxide molecule. Endogenously produced nitric oxide is produced by the endothelial cell in such a manner that the uptake of the molecule regulates the proliferation of the vascular smooth muscle cells and maintains the cellular quiescence of smooth muscle cells within the vascular architecture.
- 10 Nitric oxide is critical to numerous biological processes, including vasodilation, neurotransmission, and macrophage-mediated microorganism and tumor killing. Nitric oxide may be administrated in a chemically synthesized form as a nitric oxide donor, such as nitroglycerin dispersed within alginate matrix **32**.

Since it is such a small molecule, nitric oxide is able to diffuse rapidly across cell membranes and, depending on the conditions, is able to diffuse distances of more than several hundred microns, as is demonstrated by its regulation of smooth muscle cells, vascular dilation, tissue compliance and physiological tone of the vessel. Nitric oxide may be produced within alginate matrix **32** and delivered directly to the vessel. For example, L-arginine, a naturally occurring amino acid, and other nutraceuticals may be converted to nitric oxide within alginate matrix **32** by a group of enzymes such as nitric oxide synthases. These enzymes convert L-arginine into citrulline, producing nitric oxide in the process. In another example, nitric oxide is liberated from diazeniumdiolates, compounds that release nitric oxide into the blood stream and vascular walls.

Alginate cap **30** comprises alginate matrix **32** with, for example, crosslinked chains of mannuronate alginate monomers **62** and guluronate alginate monomers **64**. A predetermined ratio of mannuronate alginate monomers **62** and guluronate alginate monomers **64** can be selected and formed into alginate matrix **32** to provide the desired elution rates for therapeutic agents **40**. Alginate, which may be extracted from brown seaweeds such as Phaeophyceae and Laminaria, is a linear copolymer with

homopolymeric blocks of mannuronate alginate monomers **62** and guluronate alginate monomers **64**, respectively, covalently linked together in different sequences or blocks.

Alginate matrix **32** may comprise a predetermined ratio of mannuronate alginate monomers **62** and guluronate alginate monomers **64**. The alginate monomers can appear
5 in homopolymeric blocks of consecutive guluronate alginate monomers **64**, consecutive mannuronate alginate monomers **62**, alternating mannuronate alginate monomers **62** and guluronate alginate monomers **64**, or randomly organized blocks. The relative amount of each block type varies with the origin of the alginate. Alternating blocks of mannuronate alginate monomers **62** and guluronate alginate monomers **64** form the most flexible
10 chains and are more soluble at lower pH than the other block configurations. Blocks of guluronate alginate monomers **64** form stiffer chain elements, and two guluronate alginate monomeric blocks of more than six monomers each form stable crosslinked junctions with divalent cations such as Ca²⁺, Ba²⁺, Sr²⁺, and Mg²⁺ leading to a three-dimensional gel network or alginate matrix.

15 At low pH, protonized alginates form acidic gels. The homopolymeric blocks form the majority of the junctions, and the relative content of guluronate alginate monomers **64** determines the stability of the gel.

Alginate gels can develop and set at temperatures close to room temperature.
This property is particularly useful in applications involving fragile materials like cells or
20 tissue with low tolerance for higher temperatures.

The alginate polymers serve as thermally stable cold-setting gelling agents in the presence of divalent cations such as calcium ions from calcium sources. Gelling depends on the ion binding, with the divalent cation addition being important for the production of homogeneous gels, for example, by ionic diffusion or controlled acidification of calcium
25 carbonate. High guluronate alginate monomer content may produce strong, brittle gels with good heat stability, whereas high mannuronate alginate monomer content produces weaker, more elastic gels. At low or very high divalent calcium concentrations, high mannuronate alginates produce stronger gels. When the average chain lengths are not particularly short, the gelling properties correlate with the average guluronate alginate
30 monomer block length having an optimum block size of about twelve monomers, and do

not necessarily correlate with the ratio of manuronate alginate monomers **62** to guluronate alginate monomers **64**, which may be due primarily to alternating manuronate-guluronate chains. Recombinant epimerases with different specificities may be used to tailor mechanical and transport characteristics of the alginate.

5 The solubility and water-holding capacity of the alginate depends at least on pH, molecular weight, ionic strength, and the nature of the ions present. Alginate tends to precipitate below a pH of about 3.5. Alginate with lower molecular weight calcium alginate chains of less than 500 monomers shows increasing water binding with increasing size. Lower ionic strength of alginate increases the extended nature of the
10 calcium alginate chains. An alginate gel develops rapidly in the presence of divalent cations like Ca²⁺, Ba²⁺, Sr²⁺, or Mg²⁺ and acid gels may also develop at low pH. Gelling of the alginate premix occurs when divalent cations take part in the interchain ionic binding between guluronate alginate monomer blocks in the polymer chain, giving rise to a three-dimensional network. Alginates with a high content of guluronate alginate
15 monomer blocks tend to induce stronger gels. Gels made of manuronate-rich alginate are often softer and more fragile, with a lower porosity, due in part to the lower binding strength between the polymer chains and to the higher flexibilities of the molecules.

20 The gelling process is highly dependent on diffusion of gelling ions into the polymer network. Methods that may be used for the preparation of alginate gels include dialysis/diffusion and internal gelling.

25 In the dialysis/diffusion or diffusion-setting method, gelling ions are allowed to diffuse into the alginate solution. This method is commonly used for immobilization of living cells in the alginate gel. An alginate solution can also be solidified by internal gelation, internal setting, or in situ gelling. A calcium salt with limited solubility or complexed Ca²⁺-ions may be mixed into an alginate solution, resulting in the release of calcium ions, usually by the generation of acidic pH with a slowly acting acid such as D-glucono- α -lactone. The resultant alginate is a homogenous alginate macrogel. Diffusion setting and internal setting of the alginate matrix have different gelling kinetics and result in differences in their gel networks.

FIG. 2 illustrates a longitudinal view of an exemplary alginate cap, in accordance with one embodiment of the present invention. **FIG. 3** illustrates an axial cross-sectional view of the alginate cap of **FIG. 2**, with like-numbered elements referring to similar or identical elements in each illustration. **FIG. 2** and **FIG. 3** taken together, an alginate cap

- 5 **30** includes an alginate matrix **32** and a central lumen **42** axially extending through alginate matrix **32**. Alginate cap **30** covers, for example, vulnerable plaque **58** in a portion of a vessel **50**. Alginate cap **30** may include one or more therapeutic components **34** and/or cellular components **36**. Therapeutic components **34** and cellular components **36** may be dispersed uniformly within alginate matrix **32** or have a preferred distribution.
- 10 Therapeutic agents **40** are eluted from alginate cap **30**, wherein alginate matrix **32** controls the elution of therapeutic agents **40**. Alginate cap **30** provides a mechanism for controlled, time-release characteristics of therapeutic agents **40** from any therapeutic components **34** and cellular components **36** within an alginate matrix **32** of alginate cap **30**. In one embodiment, the invention provides localized delivery of one or more
- 15 therapeutic agents **40** from therapeutic components **34** dispersed within alginate cap **30** when alginate cap **30** is formed within a vessel of a mammalian recipient. In another embodiment, the invention provides long-term delivery of one or more therapeutic agents **40** via a matrix suitable for maintaining encapsulated cells and aggregates of viable cells from transplanted or implanted cells that produce such therapeutic agents.

- 20 Alginate cap **30** may have crosslinked chains of mannuronate alginate monomers **62** and guluronate alginate monomers **64** in a predetermined ratio to provide the desired mechanical strength and flexibility while controlling the elution rates for therapeutic agents **40** from alginate cap **30**.

- 25 **FIG. 3** illustrates an axial cross-sectional view of the alginate cap of **FIG. 2**, taken through line A-A'. Alginate cap **30** is in contact with an endoluminal wall **54** of a vessel **50**, and covers vulnerable plaque **58** in a portion of vessel **50**. Alginate cap **30** includes an alginate matrix **32** that may have one or more therapeutic components **34** or cellular components **36** dispersed therein. For example, therapeutic components **34** and cellular components **36** dispersed within alginate cap **30** may be uniformly dispersed
- 30 throughout, have a non-uniform profile with a higher concentration of therapeutic

components 34 or cellular components 36 nearer the central lumen 42, or have a non-uniform profile with a higher concentration of therapeutic components 34 and cellular components 36 closer to an outer surface of alginate cap 30. In another example, therapeutic components 34 and cellular components agglomerate or collect in regions 5 within alginate cap 30.

FIG. 4 is a flow diagram of a method for treating vulnerable plaque in a vessel of a mammalian body, in accordance with another embodiment of the present invention. The method includes various steps to form an alginate cap, cover or cap vulnerable plaque in the vessel, and to treat or prevent one or more medical conditions in the region 10 of alginate cap formation. The alginate cap includes an alginate matrix, and one or more therapeutic components and cellular components may be dispersed therein. Formation of the alginate cap may occur in a clinical setting, so that donor-provided cells, for example, may be harvested from a host or donor mammalian body and combined into the alginate solution immediately prior to formation of the alginate cap.

15 The alginate cap is formed within a vessel to cap vulnerable plaque and provide controlled, time-released delivery of therapeutic agents from either therapeutic components or cellular components dispersed within the alginate cap. In one embodiment, the alginate cap with an alginate matrix encapsulates and maintains the viability of cellular components, and allows the expression of therapeutic agents from the 20 cells to pass through the alginate matrix and elute into surrounding target tissues such as arterial tissues.

Desired therapeutic components and cellular components are selected along with the desired quantity, as seen at block 100. Selectable therapeutic components include, for example, an anti-coagulant, an anti-platelet drug, an anti-thrombotic drug, an anti-25 proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammatory, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin analog, paclitaxel, a paclitaxel analog, a coumadin therapy, a lipase, or a combination thereof. Selectable cellular components include, for 30 example, endothelial cells, designer-DNA manipulated cells, host-derived cells from a

host source, donor-derived cells from a donor source, pharmacologically viable cells, freeze-dried cells, or a combination thereof. The dose and constituency of added therapeutic and cellular components may be selected based on the desired treatment of the vessel and the desired elution rate of the therapeutic agents.

5 A ratio of mannuronate alginate monomers and guluronate alginate monomers may be determined to provide a predetermined elution characteristic of the alginate cap. Based on the desired elution characteristics of the therapeutic and cellular components, the ratio of mannuronate alginate monomers and guluronate alginate monomers may be determined. For example, the block length of mannuronate alginate monomers and the
10 block length of guluronate alginate monomers are selected to achieve suitable strength and flexibility of the cap, while providing controlled delivery of therapeutic and cellular components dispersed within the alginate matrix.

Prior to injection and formation of the alginate cap, the alginate premix, monomers or polymers may be sterilized by passage through a selection of submicron
15 filters, by exposure to radiation in the form of ionizing gamma or electron beams, or by other known methods of rendering a viscous solution sterile. The premix may be mixed in a suitable solvent prior to filtration and then dried, for example, by dialysis or spray drying.

An alginate solution including an alginate premix and an alginate solvent is mixed
20 prior to forming the alginate cap, as seen at block **102**. In one example, the mannuronate alginate monomers, guluronate alginate monomers, and an alginate solvent such as alcohol or water are mixed to form the alginate solution with the determined ratio of
mannuronate alginate monomers and guluronate alginate monomers. The concentration
and viscosity of the alginate solution may be reduced with the addition of aqueous
25 cellular or therapeutic components. In another example, the mannuronate alginate monomers, guluronate alginate monomers, alginate solvent, and the selected therapeutic or cellular components are combined to form the alginate solution with the determined ratio of mannuronate alginate monomers and guluronate alginate monomers. For example, endothelial cells are mixed into a formulation of alginate with appropriate
30 mannuronate and guluronate components into an alginate solution, and the alginate

solution used to form the alginate cap. In another example, an alginate premix of mannuronate alginate monomers and guluronate alginate monomers, an alginate solvent such as alcohol or water, and one or more therapeutic components and cellular components are combined to form the alginate solution.

5 In an optional step, one or more viable cell components may be harvested from the host or a donor mammalian body, and incorporated or otherwise mixed into the alginate solution prior to formation of the alginate cap in the body, as seen at block 104. The harvested cells may be further cultured to increase their numbers or further filtered to obtain the desired quantity, quality and type of cells. The harvested viable cellular
10 component, such as endogenous endothelial cells, is mixed into the alginate solution prior to injecting the alginate solution. In another example, freeze-dried cells are mixed into the alginate solution with for, example, an aqueous-based alginate solvent. The freeze-dried cells are reconstituted when the alginate cap is formed within the body. In another example, cells from either a host or donor source are preserved with trehalose and freeze-
15 dried, rendering the cells functional yet in a dehydrated state. Use of cells in a preserved fashion allows for mixing the alginate solution with the cells in advance or conjointly with the medical procedure. One skilled in the art can identify alternative cell-producing components that can be substituted for endothelial cells and provide therapeutic products from the alginate matrix.

20 A radiopaque additive such as divalent barium may be added to the alginate solution to improve fluoroscopic and radiosscopic visualization of the alginate solution during formation of the alginate cap within the body.

25 An alginate linking agent is added to the alginate solution, as seen at block 106. The added alginate linking agent comprises, for example, divalent calcium, divalent barium, divalent strontium, divalent magnesium, or a source of calcium such as a calcium salt. In one example, the alginate linking agent is added to the alginate solution immediately prior to injecting the alginate solution, due to rapid gelling and setting of the alginate matrix. In another example, the alginate linking agent is added to the alginate solution after injecting the alginate solution into the portion of the vessel. In another
30 example, the alginate linking agent is co-injected into a portion of the vessel to form the

cap. In another example, the alginate linking agent is injected into the cap-formation cavity and combined with alginate solution injected from a separate port. In another example, the alginate linking agent is deposited, applied, diffused, or otherwise transferred to an endoluminal wall of the vessel prior to injecting the alginate solution 5 into the portion of the vessel. As the alginate solution is injected, the alginate solution coagulates onto the vessel wall.

The alginate solution is injected into a cavity formed within a portion of the vessel, where the alginate solution crosslinks, gels, and hardens to form the alginate cap. The alginate cap is formed in contact with an endoluminal wall of the vessel and has a 10 central lumen axially extending through the alginate cap. The amount of alginate solution injected into the cavity is related to the length and thickness of the formed cap. Crosslinking and polymerization of alginate solution may occur in situ while at body temperature, or activated with exposure to ultraviolet light, infrared light, or thermal energy.

15 The alginate solution may be injected into a portion of the vessel with a cap formation catheter. The cap formation catheter is positioned, for example, by advancing the distal end of the cap formation catheter to a treatment site using a guidewire inserted into the vessel, as is known in the art. When the cap formation catheter is positioned, the alginate cap may be formed with one or more formation balloons attached to the catheter 20 body.

Once the alginate cap is formed, one or more therapeutic agents may be eluted from therapeutic or cellular components dispersed within the alginate cap, as seen at block 108. In one example, the eluted therapeutic agent comprises nitric oxide from entrained endothelial cells to regulate the proliferation of smooth muscle cells in the 25 vessel near the formed alginate cap. In another example, the cellular component in the alginate solution is reconstituted after the cellularized alginate cap is formed in the vessel, and therapeutic agents are produced and delivered to the vessel from the reconstituted cellular component. The immune barrier of the alginate matrix protects the cellular components. The alginate cap controls the elution of the therapeutic agent from 30 therapeutic and cellular components within the matrix.

FIG. 5 illustrates a longitudinal cross-sectional view of an alginate cap **30** being formed within a vessel **50** of a mammalian body **52**, in accordance with one embodiment of the present invention. Vessel **50** has vulnerable plaque **58** in a portion **56** of vessel **50** that may partially block the flow of fluid. A cap formation catheter **10** with a catheter body **12** has a dog-boned formation balloon **20** attached to catheter body **12** near a distal end **14** of catheter body **12**. Formation balloon **20** is inflated, for example, with contrast fluid or inflation fluid **48** injected into an interior region of formation balloon **20**. An alginate-delivery lumen **18** within catheter body **12** delivers an alginate solution **60** into a cavity **22** formed between formation balloon **20** and an endoluminal wall **54** of vessel **50** when formation balloon **20** is inflated. Slots, grooves or flexible tubes are used, for example, to guide alginate solution **60** from alginate-delivery lumen **18** into cavity **22**.

As alginate solution **60** sets and hardens, alginate cap **30** with alginate matrix **32** and a central lumen **42** is formed within vessel **50** of body **52**. With alginate cap **30** formed in the stenosed region, vulnerable plaque **58** is covered and endoluminal walls **54** of vessel **50** may be locally expanded outward to reduce the constriction and allow for increased fluid flow.

FIG. 6 illustrates a longitudinal cross-sectional view of an alginate cap **30** formed within a vessel **50** of a mammalian body **52**, in accordance with one embodiment of the present invention and as described with respect to **FIG. 5**. Alginate cap **30** includes an alginate matrix **32** in contact with vulnerable plaque **58** and an endoluminal wall **54** of vessel **50**. Therapeutic agents **40** may be eluted from alginate cap **30** from one or more therapeutic components **34** and cellular components **36** dispersed within alginate matrix **32**. Eluted therapeutic agents **40** migrate into endoluminal wall **54** and other tissues near alginate cap **30** to provide desired therapeutic effects.

FIG. 7 is a flow diagram of a method of forming an alginate cap in a vessel of a mammalian body, in accordance with one embodiment of the present invention. The method includes various steps to form an alginate cap **30** as described with respect to **FIG. 5** and **FIG. 6**.

- Cap formation catheter **10** is positioned within vessel **50**, as seen at block **120**.
- Cap formation catheter **10** has catheter body **12** with alginate-delivery lumen **18**.

Exemplary catheter body 12 has an inflation lumen for transporting inflation fluid 48 to inflate formation balloon 20, and a guidewire lumen to aid in positioning cap formation catheter 10 within the body.

Dog-boned formation balloon 20 attached to catheter body 12 near a distal end 14 of catheter body 12 is inflated, as seen at block 122. An inflation fluid or contrast fluid may be injected into formation balloon 20 to inflate and enlarge formation balloon 20.

An alginate solution 60 is injected through alginate-delivery lumen 18 into cavity 22 formed between inflated formation balloon 20 and endoluminal wall 54 of vessel 50, as seen at block 124. Alginate solution 60 is hardened with an alginate linking agent to 10 form alginate cap 30 within vessel 50.

After alginate cap 30 has been formed, formation balloon 20 is deflated and withdrawn from vessel 50 along with cap formation catheter 10, as seen at block 126.

FIG. 8 illustrates a longitudinal cross-sectional view of an alginate cap 30 being formed within a vessel 50 of a mammalian body 52, in accordance with another 15 embodiment of the present invention.

Alginate cap 30 is formed in a vessel 50 of body 52 with a system that includes a cap formation catheter 10 having a catheter body 12. A distal occlusion balloon 24 is attached to catheter body 12 near a distal end 14 of catheter body 12. A proximal occlusion balloon 26 is attached to catheter body 12 proximal to distal occlusion balloon 24. A medial formation balloon 28 is attached to catheter body 12 between distal occlusion balloon 24 and proximal occlusion balloon 26. An alginate-delivery lumen 18 contained within catheter body 12 carries alginate solution 60 to treatable portion 56 of vessel 50. Alginate cap 30 is formed over vulnerable plaque 58 from an alginate solution 60 injected through alginate-delivery lumen 18 into a cavity 22 between medial formation balloon 28 and an endoluminal wall 54 of vessel 50 when distal occlusion balloon 24 and proximal occlusion balloon 26 are inflated with an inflation fluid 48. Slots, grooves or flexible tubes may be used to guide alginate solution 60 from alginate-delivery lumen 18 into cavity 22.

FIG. 9 illustrates a longitudinal cross-sectional view of an alginate cap 30 formed 30 within a vessel 50 of a mammalian body 52, in accordance with another embodiment of

the present invention. Alginate cap 30 includes an alginate matrix 32 in contact with vulnerable plaque 58 an endoluminal wall 54 of vessel 50, and may include one or more therapeutic components 34 or cellular components 36. Therapeutic agents 40 are eluted from therapeutic components 34 and cellular components 36 dispersed within alginate matrix 32 of alginate cap 30. Therapeutic agents 40 elute from alginate cap 30 through endoluminal wall 54 of vessel 50 and into various tissues of vessel 50 near formed alginate cap 30.

FIG. 10 is a flow diagram of various steps for a method of forming alginate cap 30 in vessel 50 of mammalian body 52, in accordance with another embodiment of the present invention, and as described with respect to FIG. 8 and FIG. 9. Cap formation catheter 10 is positioned in vessel 50, as seen at block 140. Cap formation catheter 10 has catheter body 12, alginate-delivery lumen 18, and a plurality of inflation lumens.

Distal occlusion balloon 24 attached to catheter body 12 near distal end 14 of catheter body 12 is inflated, as seen at block 142. Proximal occlusion balloon 26, which is attached to catheter body 12 proximal to distal occlusion balloon 24, is inflated. Medial formation balloon 28 attached to catheter body 12 between distal occlusion balloon 24 and proximal occlusion balloon 26 is inflated. Distal occlusion balloon 24 and proximal occlusion balloon 26 are inflated to occlude vessel 50. Medial formation balloon 28 inflates to a diameter corresponding to the desired lumen diameter of alginate cap 30.

Alginate solution 60 is injected through alginate-delivery lumen 18 into cavity 22 formed between inflated distal occlusion balloon 24, inflated proximal occlusion balloon 26, inflated medial formation balloon 28, and endoluminal wall 54 of vessel 50, as seen at block 144. Alginate solution 60 hardens with an alginate linking agent to form alginate cap 30 over vulnerable plaque 58 within vessel 50.

When alginate cap 30 forms, distal occlusion balloon 24, proximal occlusion balloon 26, and medial formation balloon 28 are deflated, and cap formation catheter 10 is withdrawn from vessel 50, as seen at block 146.

FIG. 11a, FIG. 11b, FIG. 11c, FIG. 11d, FIG. 11e, and FIG. 11f illustrate longitudinal cross-sectional views of an alginate cap corresponding to steps of a method

for forming an alginate cap **30**, in accordance with another embodiment of the present invention. The illustrative steps are performed with an alginate cap formation system to treat vulnerable plaque **58** in a portion **56** of a vessel **50** of a mammalian body **52**. The system includes a cap formation catheter **10** having a catheter body **12**. An angioplasty balloon **70** is attached to catheter body **12** near a distal end **14** of catheter body **12**.
5 Angioplasty balloon **70** has an alginate linking agent **68** disposed on a surface **72** of angioplasty balloon **70**. A formation balloon **20** is attached to catheter body **12** proximal to angioplasty balloon **70**. An alginate-delivery lumen **18** is included within catheter body **12**. An alginate cap **30** is formed from an alginate solution **60** injected through
10 alginate-delivery lumen **18** into a cavity **22** between formation balloon **20** and an endoluminal wall **54** of vessel **50** when formation balloon **20** is inflated.
10

Vessel **50** in body **52** having endoluminal wall **54** and one or more areas of vulnerable plaque **58** is illustrated in FIG. 11a. Cap formation catheter **10** is positioned at a first location **74** in vessel **50**, as seen in FIG. 11b. Cap formation catheter **10** has a catheter body **12**. A guidewire **8** inserted into body **52** may be used to guide cap formation catheter **10** to the desired position in vessel **50**, as is known in the art.
15

Angioplasty balloon **70** attached to catheter body **12** near distal end **14** of catheter body **12** is inflated with an inflation fluid **48**, as seen in FIG. 11c. When in contact with endoluminal wall **54**, alginate linking agent **68** disposed on surface **72** of angioplasty balloon **70** is deposited on or otherwise transferred onto vulnerable plaque **58** and endoluminal wall **54** of vessel **50**. In an alternative embodiment, alginate linking agent **68** is pre-deposited on an outer surface of formation balloon **20**, and transferred onto endoluminal wall **54** when formation balloon **20** is inflated.
20

Angioplasty balloon **70** is deflated, and cap formation catheter **10** is repositioned at a second location **76** in vessel **50**, as seen in FIG. 11d. Second location **76**, in this example, is distal to first location **74**.
25

Angioplasty balloon **70** is re-inflated, as seen in FIG. 11e. Re-inflated angioplasty balloon **70** serves as a distal protection device. Formation balloon **20** attached to catheter body **12** proximal to angioplasty balloon **70** is inflated. Alginate solution **60** is injected through alginate-delivery lumen **18** into a cavity **22** formed
30

between formation balloon 20 and endoluminal wall 54 of vessel 50. Slots, grooves or flexible tubes are used, for example, to guide alginate solution 60 from alginate-delivery lumen 18 into cavity 22. Alginate solution 60 is hardened, for example, by alginate linking agent 68 deposited on endoluminal wall 54 and vulnerable plaque 58 of vessel 50.

5 Angioplasty balloon 70 and formation balloon 20 are deflated and withdrawn from vessel 50, as seen in FIG. 11f. Angioplasty balloon 70 may be configured to capture any embolic particles 78 when angioplasty balloon 70 and formation balloon 20 are deflated.

FIG. 12 illustrates a longitudinal cross-sectional view of an alginate cap 30
10 formed within a vessel 50, in accordance with another embodiment of the present invention. Alginate cap 30 includes an alginate matrix 32 in contact with an endoluminal wall 54 and vulnerable plaque 58 of vessel 50. Therapeutic agents 40 are eluted from alginate cap 30 when one or more therapeutic components 34 and cellular components 36 are included within alginate matrix 32. Eluted therapeutic agents 40 migrate into
15 vulnerable plaque 58, endoluminal wall 54 and other tissues near alginate cap 30 to provide a therapeutic effect.

FIG. 13 is a flow diagram of steps in a method for forming alginate cap 30 in vessel 50 of mammalian body 52, in accordance with another embodiment of the present invention and described with respect to FIG. 12 and FIG. 13.

20 Cap formation catheter 10 is positioned at first location 74 in vessel 50, as seen at block 160. Cap formation catheter 10 includes catheter body 12 with alginate-delivery lumen 18.

Angioplasty balloon 70 attached to catheter body 12 near distal end 14 of catheter body 12 is inflated with inflation fluid 48, as seen at block 162. Angioplasty balloon 70
25 has alginate linking agent 68 disposed on surface 72 of angioplasty balloon 70. Alginate linking agent 68 is deposited or otherwise transferred onto endoluminal wall 54 and vulnerable plaque 58 of vessel 50.

Angioplasty balloon 70 is deflated by withdrawing inflation fluid 48 from an interior region, as seen at block 164.

With angioplasty balloon 70 deflated to a reduced diameter, cap formation catheter 10 is repositioned at second location 76 located distally with respect to first location 74 in vessel 50, as seen at block 166. Angioplasty balloon 70 is re-inflated. Re-inflated angioplasty balloon 70 may serve as, for example, a distal protection device. A 5 formation balloon 20 attached to catheter body 12 proximal to angioplasty balloon 70 is then inflated.

Alginate solution 60 is injected through alginate-delivery lumen 18 into cavity 22 formed between formation balloon 20 and endoluminal wall 54 of vessel 50, as seen at block 168. Alginate solution 60 is hardened or otherwise set to form alginate cap 30 and 10 cover vulnerable plaque 58 in a portion 56 of vessel 50. Alginate linking agent 68 previously deposited onto endoluminal wall 54 of vessel 50 hardens alginate solution 60.

When alginate cap 30 is formed and hardened, angioplasty balloon 70 and formation balloon 20 are deflated and withdrawn from vessel 50, as seen at block 170. In one embodiment, angioplasty balloon 70 captures embolic particles 78 in a region of 15 vessel 50 between angioplasty balloon 70 and formation balloon 20 when angioplasty balloon 70 and formation balloon 20 are deflated. For example, a proximal end of angioplasty balloon 70 encloses embolic particles 78 when deflated, and a distal end of formation balloon 20 encompasses the proximal end of angioplasty balloon 70 to retain embolic particles 78 while cap formation catheter 10 is being withdrawn. In another 20 example, the proximal end of angioplasty balloon 70 includes a non-mobile calcium-rich surface that coagulates or crosslinks any alginate residuals, effectively capturing the residuals. Alternatively, embolic particles 78 may be aspirated out of vessel 50, as is known in the art.

While the embodiments of the invention disclosed herein are presently considered 25 to be preferred, various changes and modifications can be made without departing from the spirit and scope of the invention. For example, an alginate cap may provide similar protective and therapeutic benefits to other types of inflamed and diseased tissues within the body. The scope of the invention is indicated in the appended claims, and all changes that come within the meaning and range of equivalents are intended to be embraced 30 therein.

CLAIMS

What is claimed is:

5 1. An alginate cap for vulnerable plaque in a vessel of a mammalian body, the alginate cap comprising:

an alginate matrix in contact with the vulnerable plaque and an endoluminal wall of the vessel; and

10 a central lumen axially extending through the alginate cap, wherein the central lumen of the alginate cap allows fluid flow in the vessel while the alginate matrix covers the vulnerable plaque.

2. The alginate cap of claim 1 wherein the alginate matrix is formed within the vessel from an alginate solution injected into a portion of the vessel.

15

3. The alginate cap of claim 1, wherein the alginate matrix comprises a predetermined ratio of mannuronate alginate monomers and guluronate alginate monomers.

20

4. The alginate cap of claim 1 further comprising:

a therapeutic component dispersed within the alginate matrix, wherein the alginate matrix controls the elution of a therapeutic agent from the alginate cap.

25 5. The alginate cap of claim 4, wherein the therapeutic component is selected from the group consisting of an anti-coagulant, an anti-platelet drug, an anti-thrombotic drug, an anti-proliferant, an inhibitory agent, an anti-stenotic substance, heparin, a heparin peptide, an anti-cancer drug, an anti-inflammatory, nitroglycerin, L-arginine, an amino acid, a nutraceutical, an enzyme, a nitric oxide synthase, a diazeniumdiolate, a nitric oxide donor, rapamycin, a rapamycin analog, paclitaxel, a paclitaxel analog, a 30 coumadin therapy, a lipase, and a combination thereof.

6. The alginate cap of claim 1 further comprising:
a cellular component dispersed within the alginate matrix, wherein the
alginate matrix controls the elution of a therapeutic agent from the alginate cap.

5

7. The alginate cap of claim 6, wherein the cellular component is selected
from the group consisting of endothelial cells, manipulated cells of designer
deoxyribonucleic acid, host-derived cells from a host source, donor-derived cells from a
donor source, pharmacologically viable cells, freeze-dried cells, and a combination
10 thereof.

8. The alginate cap of claim 6, wherein the eluted therapeutic agent
comprises nitric oxide.

15 9. The alginate cap of claim 6, wherein the eluted therapeutic agent
comprises vascular endothelial growth factor, a biological anti-inflammatory agent,
vitamin C, acetylsalicylic acid, a lipid lowering compound, a high-density lipoprotein
cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a
blood-thinning agent, a coumadin material, an anti-cancer agent, a therapeutic
20 component, a cellular component, and a combination thereof.

10. A method of treating vulnerable plaque in a vessel of a mammalian body,
the method comprising:

25 forming an alginate cap within the vessel having a central lumen axially
extending through the alginate cap, the alginate cap in contact with the vulnerable plaque
and an endoluminal wall of the vessel; and

eluting a therapeutic agent from one of a therapeutic component or a
cellular component dispersed within the alginate cap.

11. The method of claim 10 wherein the alginate cap controls the elution of the therapeutic agent.

12. The method of claim 10, wherein the eluted therapeutic agent is selected
5 from the group consisting of vascular endothelial growth factor, a biological anti-inflammatory agent, vitamin C, acetylsalicylic acid, a lipid lowering compound, a high-density lipoprotein cholesterol, a streptokinase, a kinase, a thrombolytic agent, an anti-thrombotic agent, a blood-thinning agent, a coumadin material, an anti-cancer agent, a therapeutic component, a cellular component, and a combination thereof.

10

13. The method of claim 10, wherein the eluted therapeutic agent comprises nitric oxide to regulate the proliferation of smooth muscle cells in the vessel near the formed alginate cap.

15

14. The method of claim 10 further comprising:
mixing an alginate solution including an alginate premix and an alginate solvent;
adding an alginate linking agent into the alginate solution; and
injecting the alginate solution into a portion of the vessel with a cap
formation catheter.

20
15. The method of claim 14, wherein the alginate linking agent is added to the alginate solution prior to injecting the alginate solution into the portion of the vessel.

25

16. The method of claim 14, wherein the alginate linking agent is added to the alginate solution after injecting the alginate solution into the portion of the vessel.

30

17. The method of claim 14, wherein the alginate linking agent is deposited on an endoluminal wall of the vessel prior to injecting the alginate solution into the portion of the vessel.

18. The method of claim 14, wherein the added alginate linking agent comprises one of divalent calcium, divalent barium, divalent strontium, or divalent magnesium.

5

19. The method of claim 14 further comprising:
determining a ratio of mannuronate alginate monomers and guluronate alginate monomers to provide a predetermined elution characteristic of the alginate cap;
and
10 combining mannuronate alginate monomers, guluronate alginate monomers, the alginate solvent, and the therapeutic component or the cellular component to form the alginate solution with the determined ratio of mannuronate alginate monomers and guluronate alginate monomers.

15 20. The method of claim 14 further comprising:
harvesting a viable cellular component from one of a host or a donor; and
mixing the harvested viable cellular component into the alginate solution prior to injecting the alginate solution.

20 21. The method of claim 20, wherein the harvested viable cellular component comprises endogenous endothelial cells.

22. The method of claim 10 further comprising:
reconstituting the cellular component in the alginate cap, wherein the
25 eluted therapeutic agent is released from the reconstituted cellular component.

23. A system for treating vulnerable plaque in a vessel of a mammalian body, the system comprising:
a cap formation catheter having a catheter body;

a dog-boned formation balloon attached to the catheter body near a distal end of the catheter body; and

an alginate-delivery lumen within the catheter body, wherein an alginate cap is formed over the vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated.

24. A method of forming an alginate cap in a vessel of a mammalian body, the method comprising:

10 positioning a cap formation catheter in the vessel, the cap formation catheter having a catheter body;

inflating a dog-boned formation balloon attached to the catheter body near a distal end of the catheter body;

15 injecting an alginate solution through an alginate-delivery lumen into a cavity formed between the inflated formation balloon and an endoluminal wall of the vessel; and

hardening the alginate solution to form the alginate cap, wherein the alginate cap covers vulnerable plaque in a portion of the vessel.

20 25. The method of claim 24 further comprising:

deflating the formation balloon; and

withdrawning the cap formation catheter from the vessel.

25 26. A system for treating vulnerable plaque in a vessel of a mammalian body, the system comprising:

a cap formation catheter having a catheter body;

a distal occlusion balloon attached to the catheter body near a distal end of the catheter body;

30 a proximal occlusion balloon attached to the catheter body proximal to the distal occlusion balloon;

a medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon; and

an alginate-delivery lumen within the catheter body, wherein an alginate cap is formed over the vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the medial formation balloon and an endoluminal wall of the vessel when the distal occlusion balloon and the proximal occlusion balloon are inflated.

27. A method of forming an alginate cap in a vessel of a mammalian body, the
10 method comprising:

positioning a cap formation catheter in the vessel, the cap formation catheter having a catheter body;

inflating a distal occlusion balloon attached to the catheter body near a distal end of the catheter body;

15 inflating a proximal occlusion balloon attached to the catheter body proximal to the distal balloon;

inflating a medial formation balloon attached to the catheter body between the distal occlusion balloon and the proximal occlusion balloon;

20 injecting an alginate solution through an alginate-delivery lumen into a cavity formed between the inflated distal occlusion balloon, the inflated proximal occlusion balloon, the inflated medial formation balloon, and an endoluminal wall of the vessel; and

hardening the alginate solution to form the alginate cap, wherein the alginate cap covers vulnerable plaque in a portion of the vessel.

25

28. The method of claim 27 further comprising:

deflating the distal occlusion balloon, the proximal occlusion balloon, and the medial formation balloon; and

30 withdrawing the cap formation catheter from the vessel.

29. A system for treating vulnerable plaque in a vessel of a mammalian body, the system comprising:
- a cap formation catheter having a catheter body;
 - an angioplasty balloon attached to the catheter body near a distal end of
 - 5 the catheter body, the angioplasty balloon having an alginate linking agent disposed on a surface of the angioplasty balloon;
 - a formation balloon attached to the catheter body proximal to the angioplasty balloon; and
 - an alginate-delivery lumen within the catheter body, wherein an alginate
 - 10 cap is formed over the vulnerable plaque from an alginate solution injected through the alginate-delivery lumen into a cavity between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated.

30. A method of forming an alginate cap in a vessel of a mammalian body, the method comprising:
- positioning a cap formation catheter at a first location in the vessel, the cap formation catheter having a catheter body;
 - inflating an angioplasty balloon attached to the catheter body near a distal end of the catheter body, the angioplasty balloon having an alginate linking agent
 - 20 disposed on a surface of the angioplasty balloon;
 - depositing the alginate linking agent on an endoluminal wall of the vessel;
 - deflating the angioplasty balloon;
 - repositioning the cap formation catheter at a second location in the vessel, the second location in the vessel distal to the first location in the vessel;
 - 25 re-inflating the angioplasty balloon;
 - inflating a formation balloon attached to the catheter body proximal to the angioplasty balloon;
 - injecting an alginate solution through an alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel; and

hardening the alginate solution to form the alginate cap, wherein the alginate solution is hardened by the alginate linking agent deposited on the endoluminal wall of the vessel, wherein the alginate cap covers vulnerable plaque in a portion of the vessel.

5

31. The method of claim 30, wherein the re-inflated angioplasty balloon serves as a distal protection device.

10

32. The method of claim 30 further comprising:
deflating the angioplasty balloon and the formation balloon; and
withdrawing the cap formation catheter from the vessel.

33. The method of claim 32, wherein the angioplasty balloon captures embolic particles when the angioplasty balloon and the formation balloon are deflated.

15

34. A system for forming an alginate cap in a vessel of a mammalian body, the system comprising:

a cap formation catheter having a catheter body and an alginate-delivery lumen within the catheter body; and

20

at least one formation balloon attached proximal to a distal end of the catheter body, wherein the alginate cap is formed in the vessel when the cap formation catheter is inserted into the vessel and an alginate solution is injected through the alginate-delivery lumen into a cavity formed between the formation balloon and an endoluminal wall of the vessel.

25

35. A method of forming an alginate cap in a vessel of a mammalian body, the method comprising:

inserting a cap formation catheter into the vessel, the cap formation catheter having at least one formation balloon;

- injecting an alginate solution into a cavity formed between the formation balloon and an endoluminal wall of the vessel when the formation balloon is inflated;
 - hardening the alginate solution to form the alginate cap; and
 - withdrawing the cap formation catheter from the vessel, wherein the
- 5 formed alginate cap is in contact with the endoluminal wall of the vessel and includes a central lumen axially extending through the alginate cap.

ABSTRACT OF THE DISCLOSURE

The invention provides an alginate cap for vulnerable plaque in a vessel of a
5 mammalian body. The alginate cap includes an alginate matrix in contact with the
vulnerable plaque and an endoluminal wall of the vessel. A central lumen extends axially
through the alginate matrix. The central lumen of the alginate cap allows fluid flow in
the vessel while the alginate matrix covers the vulnerable plaque. Methods and systems
to form an alginate cap with the vessel and methods to treat the vessel are also disclosed.

10

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11a




FIG. 11b




FIG. 11c




FIG. 11d




FIG. 11e




FIG. 11f




FIG 12




FIG. 13

